

Human HLA-A*02:01&B2M&KKLC1 (ILNFPHSI) Monomer Protein



Cat. No. MHC-HM493

Description

Source	Recombinant Human HLA-A*02:01&B2M&KKLC1 (ILNFPHSI) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and ILNFPHSI peptide.
Accession	A0A140T913(HLA-A*02:01)&P61769(B2M)&ILNFPHSI
Molecular Weight	The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Supplied as 0.22 µm filtered solution in PBS (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

ILNFPHSI is a peptide epitope derived from KKLC1 (also known as Kita-kyushu lung cancer antigen 1, CT83 or CXorf61) that is naturally processed and presented on the cell surface in complex with MHC class I molecules. This peptide, together with binding moieties that specifically recognize the peptide-MHC complex, provides a valuable basis for the development of therapeutic agents capable of selectively targeting KKLC1-expressing cancer cells, and holds particular promise for the treatment of malignancies such as non-small cell lung cancer (adenocarcinoma and squamous subtypes) and esophageal cancer.


Assay Data

Bis-Tris PAGE



Human HLA-A*02:01&B2M&KKLC1 (ILNFPHSI) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human HLA-A*02:01&B2M&KKLC1 (ILNFPHSI) Monomer is greater than 95% as determined by SEC-HPLC.